CAR-T cells are a major therapeutic innovation in the management of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in 3rd line or more. Kymriah® and Yescarta® are the first CAR-T with Marketing Authorization and coverage by the French Health Insurance. Their clinical interest has been demonstrated in non-comparative phase 1-2 trials.

The non-comparative design of the pivotal trials, the lack of data on patients' quality of life and drug consumption, as well as the very high cost of CAR-T (about € 320,000 for one treatment) warrant further studies.

This prospective non-comparative study aims to describe in real life the quality of life of patients treated with CAR-T cells, real world drug use and patients' experience feedback.

Inclusion Criteria:

• Over 18 years old
• Eligible for treatment with CAR-T cells (outside any clinical trial) in an indication of DLBCL and for which treatment is scheduled
• Follow-up in the Hematology department of the Hospices Civils de Lyon
• Without major psychiatric disorder likely to interfere with the conduct of the study, in the opinion of the investigator
• Having given his non-opposition to participate in the study.

Exclusion Criteria:

• In an institution
• Under legal protection

Patients with diffuse large B-cell lymphoma treated with CART-cells in the center during the inclusion period.